<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04630366</url>
  </required_header>
  <id_info>
    <org_study_id>NST-1024-01</org_study_id>
    <nct_id>NCT04630366</nct_id>
  </id_info>
  <brief_title>A Phase 1, First Time in Humans Study of NST-1024</brief_title>
  <official_title>A Phase 1, First Time in Man Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of NST-1024 in Healthy Subjects and Otherwise Healthy Subjects With Elevated Triglycerides</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NorthSea Therapeutics B.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NorthSea Therapeutics B.V.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A first time in man study of NST-1024&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase 1, First Time in Man Study to Evaluate the Safety, Tolerability, and Pharmacokinetics&#xD;
      of NST-1024 in Healthy Subjects and Otherwise Healthy Subjects with Elevated Triglycerides.&#xD;
      This will be a double-blind, randomised, placebo-controlled, single and multiple oral dose&#xD;
      study conducted in 2 parts. In part A up to 6 cohorts of 8 healthy volunteers will receive&#xD;
      single ascending doses of NST-1024 or matching placebo. I part B up to 4 cohorts of 10&#xD;
      otherwise healthy volunteers, with elevated triglycerides will receive daily multiple&#xD;
      ascending doses of NST-1024 for 14 days&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 27, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>4 weeks</time_frame>
    <description>incidence and severity of adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC</measure>
    <time_frame>3-17 days</time_frame>
    <description>Area under the PK curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>3-17 days</time_frame>
    <description>Maximum plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half life</measure>
    <time_frame>3-17 days</time_frame>
    <description>time to reduction in plasma levels by 50%</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Hypertriglyceridemia</condition>
  <arm_group>
    <arm_group_label>NST-1024</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NST-1024 capsules given once daily for up to 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo capsules to NST-1024 given once daily for up to 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NST-1024</intervention_name>
    <description>NST-1024</description>
    <arm_group_label>NST-1024</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo to NST-1024</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  BMI 18-32 kg/m2&#xD;
&#xD;
          -  In good health&#xD;
&#xD;
          -  Females will not be pregnant or lactating. Females of childbearing potential must&#xD;
             agree to use contraception&#xD;
&#xD;
          -  Male subjects must agree to use contraception and refrain from donation of sperm&#xD;
&#xD;
          -  Able to comprehend and willing to sign an ICF and to abide by the study restrictions.&#xD;
&#xD;
          -  Subjects must have TG levels &gt; 150 mg/dL at screening (Part B only).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Significant history or clinical manifestation of any metabolic, allergic,&#xD;
             dermatological, hepatic, renal, haematological, pulmonary, CV, gastrointestinal,&#xD;
             neurological, respiratory, endocrine, or psychiatric disorder, as determined by the&#xD;
             Investigator (or designee).&#xD;
&#xD;
          -  History of febrile illness within 7 days prior to the first dose of study drug or&#xD;
             subjects with evidence of active infection.&#xD;
&#xD;
          -  History of stomach or intestinal surgery or resection that would potentially alter&#xD;
             absorption and/or excretion of orally administered drugs (uncomplicated appendectomy&#xD;
             and hernia repair will be allowed).&#xD;
&#xD;
          -  Aspartate aminotransferase, ALT, GGT, ALP, or total bilirubin &gt; 1.2 Ã— ULN at Screening&#xD;
             or (first) Check-in, confirmed by 1 repeat if necessary&#xD;
&#xD;
          -  History of alcoholism or drug/chemical abuse within 2 years prior to Check-in.&#xD;
&#xD;
          -  Participation in a clinical study involving administration of an investigational drug&#xD;
             (new chemical entity) in the past 90 days or 5 half-lives (whichever is longer) prior&#xD;
             to dosing.&#xD;
&#xD;
          -  Use of tobacco- or nicotine-containing products within 1 month prior to Screening, or&#xD;
             positive cotinine test at Screening or Check-in.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Patrick Round, MBBS</last_name>
    <phone>+447979502770</phone>
    <email>patrick.round@northseatherapeutics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Covance Leeds Clinical Research Unit</name>
      <address>
        <city>Leeds</city>
        <state>West Yorkshire</state>
        <zip>LS2 9LH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Davies, PhD</last_name>
      <phone>011303945200</phone>
      <email>Anna.Davies@covance.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 5, 2020</study_first_submitted>
  <study_first_submitted_qc>November 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 16, 2020</study_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertriglyceridemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

